STAT

The Gates Foundation rolls outs details of its new biotech, one without a profit motive

The Bill and Melinda Gates Foundation is building a biotech nonprofit, focusing on diseases that disproportionately affect the poor.

There’s a new biotech in town. And it doesn’t care about making money.

The Bill and Melinda Gates Foundation has spun out a nonprofit biotech offspring, the Bill and Melinda Gates Medical Research Institute. With funding of $273 million for its first four years, the organization is in an enviable position.

“We don’t have to worry about revenue, return on investment. Our bottom line is lives saved. So it’s a pretty exciting place to be,” Dr. Penny

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks